Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4Rituximab 4Immunoglobulins, Intravenous 4efgartigimod alfa 3Tacrolimus 3Mycophenolic Acid 3Hizentra 3HBM9161 3Data Collection 2Azathioprine 2tofacitinib 1telitacicept 1ravulizumab 1iscalimab 1gamma-Globulins 1apraclonidine 1Thymectomy 1Telemedicine 1Sugammadex 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisone 1Prednisolone 1Plasmapheresis 1Plasma Exchange 1Neurofeedback 1Neostigmine 1Muscle Stretching Exercises 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myasthenia Gravis × iscalimab × Clear all
NCT02565576 2021-01-05

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Novartis

Phase 2 Completed
44 enrolled 17 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡